Related Experiment Video
Updated: Aug 19, 2025

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Targeting the FGF/FGFR axis and its co-alteration allies.
1Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University, Tokyo; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Fibroblast growth factor (FGF)/FGF receptor (FGFR) alterations are linked to poorer cancer prognosis and often occur with co-alterations. Combination therapy targeting both cyclin and FGFR pathways shows promise for treating these malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Fibroblast growth factor (FGF)/FGF receptor (FGFR) pathway alterations are implicated in various cancers.
- Co-occurring genetic alterations (co-alterations) may influence cancer progression and treatment response.
- Understanding the FGF/FGFR landscape and its co-alterations is crucial for developing targeted therapies.
Purpose of the Study:
- To analyze the FGF/FGFR and co-alteration cancer landscape.
- To investigate the prognostic impact of FGF/FGFR alterations and associated co-drivers.
- To evaluate the efficacy of combination therapies targeting co-altered pathways.
Main Methods:
- Analysis of FGF/FGFR-altered pathways, prognosis, and co-alterations using cBioPortal (N=7574).
- Evaluation of therapeutic outcomes in patients treated with FGFR inhibitors at the University of California San Diego Molecular Tumor Board (MTB) (N=16).
- Comparison of overall survival (OS) between patients with and without FGF/FGFR alterations.
Main Results:
- Patients with FGF/FGFR alterations had significantly shorter overall survival (OS) compared to those without (23.1 vs. 26.4 months, P=0.038).
- TP53 (70%), cell cycle (58%), PI3K (55%), and MAPK (65%) were the most frequent co-altered pathways.
- Combination therapy with a CDK4/6 inhibitor (palbociclib) and an FGFR inhibitor (lenvatinib) resulted in partial responses (PR) in 50% of patients with cyclin pathway co-alterations.
Conclusions:
- FGF/FGFR alterations are associated with poor prognosis and frequently accompanied by pathogenic co-aberrations.
- Malignancies with co-alterations in both cyclin and FGFR pathways can be effectively co-targeted.
- Targeting co-activated cyclin and FGFR pathways with CDK4/6 and FGFR inhibitors demonstrates therapeutic potential.
More Related Videos
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Related Concept Videos
TGF - β Signaling Pathway
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle
Regulation of Angiogenesis and Blood Supply
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical,...
Intracellular Signaling Affects Focal Adhesions
Some...